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Abstract 
Background: Obstructive sleep apnea syndrome (OSAS) is associated with repeated apnea-
induced sympathetic surges leading to specific alterations of the power spectrum of heart rate 
variability (HRV). Sympathetic dysfunction evolves early in idiopathic Parkinson’s disease 
(PD), but the consequences on cardiac autonomic response to OSAS have not been studied so 
far in PD patients. 
Methods: Sixty-two patients with PD (35 without OSAS (PD-wo), 27 with OSAS (PD-
OSAS)) and 62 age-matched control subjects (25 without OSAS (Co-wo), 37 with OSAS 
(Co-OSAS)) were included. HRV variables – including mean R-R interval, standard deviation 
of all normal-to-normal R-R intervals (SDNN), both low frequency (LF) and high frequency 
(HF) power bands, and the LF/HF ratio – were computed automatically from full-night 
polysomnography and calculated separately for each sleep stage. 
Results: HRV variables were similar in PD-wo and PD-OSAS. In contrast, Co-OSAS showed 
significantly higher LF power in NREM1 and NREM2 sleep and higher LF/HF ratio in 
NREM1, NREM2 and slow wave sleep than Co-wo. Similarly, correlations between HRV 
variables and parameters of OSAS severity were found only in controls but not in PD patients. 
Conclusion: Our results suggest that the sympathetic response to OSAS is blunted in PD, 
giving further clinical evidence of the sympathetic denervation commonly observed in this 
neurodegenerative disorder. 
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Introduction 
Increased vascular morbidity in patients with obstructive sleep apnea syndrome 
(OSAS) is believed to be caused by abnormal autonomic cardiovascular regulation [1]. In this 
line, obstructive sleep-related apnea events are characterized by progressive bradycardia 
during respiratory effort and abrupt tachycardia after reopening of the airways, which leads to 
cyclical variations of heart rate [2]. Studies using spectral analysis of heart rate variability 
(HRV) have shown that OSAS is accompanied by an increase of low frequency power bands, 
which is believed to reflect sympathetic activity [3]. Likewise, both increased sympathetic 
nerve activity and high levels of circulating norepinephrine during wakefulness have been 
observed in patients with OSAS [4-6]. During sleep, obstructive apneas are accompanied by 
transient vasoconstriction in the limbs, again suggesting apnea-induced sympathetic activation 
[7]. Finally, there is evidence that alteration of HRV and overactivity of the sympathetic 
nervous system is reversible during treatment with continuous positive airway pressure [6, 8]. 
The effects of OSAS on cardiac autonomic function may be altered in patients with 
neurological conditions affecting the autonomic nervous system (ANS). Earlier studies in 
patients with familial dysautonomia or pure autonomic failure reported that even severe 
apneas were not associated with the usual cardiac response, suggesting a decoupling of the 
heart rate from the respiratory cycle in neurodegenerative disease [9, 10].  
In idiopathic Parkinson’s disease (PD), there is growing evidence for sympathetic 
denervation of the heart. Neuroimaging studies using different sympathiconeural imaging 
agents demonstrated reduced sympathetic innervation of the heart in patients with PD [11, 
12]. Considering the important pathophysiological involvement of the ANS in OSAS and its 
primary impairment in PD, it is surprising that the cardiac autonomic response to OSAS has 
not yet been studied in PD patients. Therefore, the primary goal of this study was to test the 
hypothesis whether the normal sympathetic response to OSAS is blunted in PD. In addition, 
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we aimed at identifying possible consequences of this sympathetic denervation in PD patients 
with OSAS. 
 
Methods  
This retrospective study was conducted at the Department of Neurology of the 
University Hospital of Zurich, Switzerland.  
 Subjects. We analyzed the data of 115 consecutive patients with idiopathic Parkinson’s 
disease (PD). All patients were examined in our Movement Disorders outpatient clinic and in 
our sleep laboratory between January 2005 and June 2010. Fifty-three PD patients were 
diagnosed with OSAS (PD-OSAS), and 59 had no clinical or polysomnographic signs of 
OSAS (PD-wo). Three PD patients with apneas of mainly central origin were excluded. 
As control groups, we included 80 consecutive patients, who have been diagnosed 
with OSAS (Co-OSAS), and 53 subjects without OSAS (Co-wo), i.e. without 
polysomnographic abnormalities. We excluded subjects with cardiovascular disease, cardiac 
arrhythmia, concomitant diabetes, neurological disorders, additional sleep-wake disorders 
such as narcolepsy, restless legs syndrome (RLS), periodic limb movements during sleep 
(PLMS), rapid eye movement (REM) sleep behavior disorder (RBD), and intake of 
betablockers. 
PD patients were older than control subjects (PD-wo: 65 ± 10 years, PD-OSAS: 66 ± 8 
years; Co-wo: 46 ± 15 years, Co-OSAS: 51 ±13 years). Since age is known to have a major 
impact on cardiac autonomic function, we aimed for a better matching of age and selected the 
62 youngest PD patients and the 62 oldest control subjects for this study. We therefore 
included 35 PD-wo (mean age: 58 ± 6 years), 27 PD-OSAS (59 ± 6 years), 25 Co-wo (57 ± 12 
years), and 37 Co-OSAS (59 ± 8 years). 
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Clinical assessments. The diagnosis of Parkinson’s disease was made according to 
international diagnostic criteria [13]. Motor symptoms and disease severity were assessed 
according to the motor subset of the Unified Parkinson’s Disease Rating Scale (UPDRS III) in 
off condition and by the Hoehn & Yahr staging, respectively. Excessive daytime sleepiness 
(EDS) was diagnosed if the score of the Epworth sleepiness scale was ≥ 10.  
Polysomnography. All subjects underwent one full-night polysomnography 
(Somnologica software). The recordings were performed from 11.00 PM until 7.00 AM using a 
16-channel recording system (Embla A10, Embla, Broomfield, CO). Polysomnography 
included electroencephalographic recording (C3-A2, O2-A1), electro-oculography, chin and 
bilateral anterior tibialis muscles electromyography, oro-nasal thermistor, nasal flow pressure 
sensor and measurement of thoracic and abdominal movements (impedance). Oxygen 
saturation (SaO2) was continuously determined with a finger oximeter. Scoring of sleep stages 
and respiratory events was performed visually using standardized criteria [14, 15]. Apnea was 
defined by a cessation of oro-nasal airflow longer than 10 seconds, and hypopnea by a 
reduction of oro-nasal airflow by at least 50% lasting more than 10 seconds and accompanied 
by an arousal or SaO2 reduction of ≥ 3%. The apnea-hypopnea index (AHI) was calculated by 
the mean number of apneas and hypopneas per hour. Furthermore, mean SaO2, time with 
SaO2 below 90% (SaO2 < 90%), and oxygen desaturation-index (ODI) were calculated. OSAS 
was diagnosed in the presence of AHI ≥ 5/h with predominantly obstructive apneic events.  
Heart rate variability analysis. Polysomnography included a two-channel 
electrocardiogram (ECG) which allowed subsequent analysis of heart rate variability (HRV) 
by means of a specific HRV-module of the Somnologica software. Heart rate is expressed as 
average R-R interval in milliseconds, i.e. the mean interval between successive normal QRS 
complexes. HRV gives information about how the heart rate varies in time. All R-R intervals 
were processed; artifacts were identified and removed by a specific detection algorithm. 
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Polysomnographic recordings were divided into continuous 5-minute segments. The most 
prevailing sleep stage was allocated to every 5-minute segment allowing estimation of mean 
values per sleep. Calculation of HRV variables in relation to sleep stages is necessary because 
there is considerable variability of HRV variables between different sleep stages, as shown in 
healthy subjects [16].  
For each 5-minute segment, both time-domain and frequency-domain HRV parameters 
were computed. The time-domain HRV variables are calculated based on different aspects of 
the beat-to-beat intervals [16]. For the purpose of this study, the time-domain pattern was 
estimated by assessing the mean R-R intervals and the standard deviation of normal R-R 
intervals (SDNN) for each consecutive 5-minute segment. The frequency-domain HRV 
variables give general information on the power distribution across frequencies. They were 
obtained by a Fast Fourier spectral analysis of the R-R sequence. The power was calculated 
for low frequency (LF, 0.04 – 0.15 Hz) and high frequency bands (HF, 0.15 – 0.40). In 
addition, LF/HF ratio was calculated. Extensive literature exists on the physiological and 
clinical interpretation of the different power bands [17]. Briefly, the HF power is considered 
to reflect the parasympathetic (vagal) modulation of the heart rate, whereas the LF power 
reflects both sympathetic and parasympathetic activity [17]. The LF/HF ratio is believed to be 
a measure of the sympatho-vagal balance; higher values for this ratio may therefore imply 
either an increase in sympathetic dominance or a shift towards decreased vagal tone, or both. 
Data analysis and statistics. Statistical analyses were performed using SPSS (version 
19.0). Group data are described by means and standard deviations (SD). For univariate 
analysis we used Student’s t and Mann–Whitney U tests for numerical scale variables and χ2-
test for nominal scale variables. Testing of differences in HRV variables and demographic 
data between multiple groups was performed by the Kruskal-Wallis H test. We used 
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Spearman rho coefficient for correlation analysis between polysomnographic findings and 
HRV variables. Significance was accepted at p < 0.05. 
 
Results 
Demographic, clinical and polysomnographic data of the 62 control subjects and the 
62 PD patients are given in Table 1. The four groups did not differ in age and sex distribution. 
Group comparisons did not reveal any differences in the quantitative distribution of sleep 
stages. In control subjects but not in PD patients, the group with OSAS had higher arousal 
indices (20.3 ± 20.1 vs. 10.6 ± 7, p = 0.01). The prevalence of EDS was significantly higher in 
Co-OSAS compared to Co-wo (p = 0.04) and PD-OSAS (p = 0.04), while there were no 
differences in EDS between PD-OSAS and PD-wo. OSAS severity was similar between PD-
OSAS and Co-OSAS for most parameters, but oxygen desaturation was milder in PD-OSAS 
(Table 2).  
In terms of PD symptoms, PD-wo and PD-OSAS had similar prevalences of 
dyskinesia (36% vs. 33%, p = 0.54), wearing-off (33% vs. 30%, p = 0.51), hallucinations 
(17% vs. 29%, p = 0.28), RBD (62% vs. 71%, p = 0.32), insomnia (56% vs. 52%, p = 0.48) 
and autonomic disturbances (58% vs. 59%, p = 0.59). Furthermore, PD-wo and PD-OSAS did 
not differ in disease duration, disease severity and dopaminergic treatment (Table 1 and 3).   
Heart rate variability measures: comparison between Co-wo and PD-wo. In all 
behavioral stages, the mean R-R interval was lower (faster heart rate) in Co-wo than in PD-
wo (wake: 869 ± 115ms vs. 964 ± 182ms, p = 0.02; NREM1: 927 ± 136ms vs. 1033 ± 201ms, 
p = 0.02; NREM2: 938 ± 141ms vs. 1035 ± 198ms, p = 0.03; SWS: 909 ± 141ms vs. 1036 ± 
210ms, p = 0.009; REM: 919 ± 123ms vs. 1011 ± 189ms, p = 0.03). On the other hand, 
SDNN and the frequency-domain indices LF, HF and the LF/HF ratio were similar in Co-wo 
and PD-wo (Figure 1).  
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Heart rate variability measures: comparison between Co-wo and Co-OSAS. In control 
subjects, the presence of OSAS was associated with a significant increase in the LF 
component in both NREM1 and NREM2 sleep and an increase in the LF/HF ratio in NREM1, 
NREM2 and slow wave sleep (Figure 1). Values for mean R-R and SDNN did not differ 
between the two groups. 
Heart rate variability measures: comparison between Co-OSAS and PD-OSAS. The 
mean R-R interval and SDNN were similar between Co-OSAS and PD-OSAS. In Co-OSAS, 
however, the LF component was higher during wakefulness (p = 0.04), NREM1 (p = 0.02) 
and REM sleep (p = 0.02) and the LF/HF ratio was higher during NREM1 (p = 0.04) and 
REM sleep (p = 0.008) (Figure 1). 
Heart rate variability measures: comparison between PD-wo and PD-OSAS. The two 
PD groups did not differ in any of the HRV measures (Figure 1). 
Correlates of HRV parameters. In control subjects, AHI significantly correlated with 
LF and LF/HF ratio in both NREM1 and NREM2 sleep, and AHI was inversely correlated 
with HF during wakefulness and NREM1 sleep (Table 4). Similar correlations were revealed 
for ODI. In PD patients, on the other hand, AHI and ODI did not correlate with any of the 
HRV variables.  
Correlates of cortical arousal reaction. In control subjects – but not in PD patients – 
significant correlations were found between arousal index and HRV measures (Table 4). In 
addition, while control subjects showed a highly significant correlation between AHI and 
arousal index (rho = 0.6, p < 0.001), this relationship was not found in PD patients (rho = 
0.06, p = 0.64) (figure 2).         
Influence of autonomic disturbances in PD-OSAS. PD-OSAS patients with a history or 
clinical signs of autonomic disturbances (AD) (56%) – including obstipation (n = 9), urinary 
incontinence (n = 4), erectile dysfunction (n = 8), orthostatic dysregulation (n = 3) and 
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sweating disturbances (n = 4) – had significantly lower heart rates in wakefulness, NREM1, 
NREM2 and REM sleep compared to PD-OSAS without AD (44%) (Figure 3).  
 
Discussion 
The main finding of our study is the lack of difference in HRV variables between PD 
patients with and without OSAS. In control subjects, on the other hand, the presence of OSAS 
was associated with a significant increase in the low frequency power spectrum during 
NREM1 and NREM2 sleep and of the LF/HF ratio during NREM1, NREM2 and slow wave 
sleep. In other words, PD patients lack the normal sympathetic response to OSAS, thus 
supporting our initial hypothesis. In the same line and again in contrast to controls, parameters 
of OSAS severity such as AHI, ODI and SaO2 < 90%  did not correlate with any HRV 
parameters in PD patients. Further novel findings of this study comprise the reduced cortical 
arousal frequency of PD-OSAS compared to Co-OSAS, and the effect of autonomic 
disturbances on heart rate in PD-OSAS. 
The increase of LF power and LF/HF ratio’s in the control group with OSAS indicates 
enhanced sympathetic drive induced by the repeated apneic events, which is in line with 
previous studies [1]. To our best knowledge, however, cardiac autonomic response to OSAS 
has not been assessed yet in PD. Several mechanisms may contribute to the observed impaired 
cardiac autonomic response to OSAS in PD. First, it is conceivable that the blunted effect of 
OSAS on cardiac autonomic function reflects the loss of cardiac sympathetic noradrenergic 
innervation in PD. Evidence of cardiac sympathetic denervation comes mainly from 
neuroimaging studies, demonstrating decreased myocardial radioactivity after injection of 
sympathiconeural imaging agents in a majority of PD patients. Using 
123
I-
metaiodobenzylguinidine scanning, cardiac sympathetic denervation was found in early stages 
of PD, and even in the absence of clinical signs of autonomic failure [18]. In accordance with 
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these findings, a postmortem pathology study found a marked loss of tyrosine hydroxylase 
immunoreactivity, a marker for sympathetic nerves, in epicardial nerves or myocardial tissue 
[12].  
Second, autonomic dysfunction in PD is not limited to the heart. According to the 
study of Braak et al., the neurodegenerative process in many PD patients begins in the 
medulla oblongata and progresses in an ascending way to involve, already at early stages, 
various nuclei of the brainstem and also the hypothalamus and other parts of the basal ganglia 
[19]. The dorsal nucleus of the vagus and the locus coeruleus (LC) are among the first 
structures to be affected by the disease process. While the former gives rise to 
parasympathetic vagal neurons, the latter represents the principal source of brain 
norepinephrine. Besides of its major role in mediating arousal and shifts of behavior, the LC 
is also believed to be implicated in the central regulation of cardiovascular function [20]. It is 
therefore conceivable that destruction of pathways of the central autonomic nervous system 
involved in the regulation of cardiovascular function may additionally contribute to the 
neurocardiological abnormalities in PD patients with OSAS.  
Third, differences in OSAS characteristics between PD patients and control subjects 
should be taken into consideration. Although our two groups with OSAS did not differ in 
AHI, ODI, mean apnea duration and mean SaO2, the PD patients with OSAS maintained a 
more favorable respiratory profile, as reflected by less pronounced minimal SaO2 and fewer 
time spent with SaO2 < 90%.  
An unexpected observation of the present study was the lack of correlation between 
AHI and arousal index in PD patients – in controls this relationship was highly significant. 
Several reasons may explain this decrease of arousability in PD. First, sympathetic activation, 
as measured by heart rate spectral analysis, has been reported to precede visually detected 
cortical arousals [21]. Thus, an intact sympathetic nervous system may play a relevant role in 
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conveying the end-apnea effort to a cortical arousal reaction. Second, Onodera et al. studied 
ventilatory response to hypoxia and perception of dyspnoea in 25 PD patients and found a 
subnormal hypoxic response accompanied by an impaired perception of dyspnea [22]. Third, 
multiple components of the central arousal system are known to be damaged in PD, including 
the noradrenergic LC, the serotonergic dorsal raphe, the cholinergic pedunculopontine 
nucleus, the hypothalamic hypocretin system and the cholinergic neurons in the basal 
forebrain [23]. Intriguingly, the assumption of a decreased arousability seems to be 
inconsistent with the fact that OSAS severity tended to be milder in PD patients, because one 
would expect more severe apneas under this condition. On the other hand, however, even in 
healthy subjects about 30% of apneas and hypopneas are not accompanied by cortical arousals 
[24]. Furthermore, factors such as deeper sleep stage or higher sleep pressure are known to 
increase the cortical arousal threshold to respiratory events [25]. In other words, cortical 
arousal must not be regarded as a necessary prerequisite for apnea termination, but rather as a 
cortical consequence, which depends on the intensity of the inspiratory effort and on the 
integrity of several components of the central arousal system. Presumably, mechanoreceptor 
feedback from the respiratory muscles to the medullary respiration center can bring apneas to 
an end without activation of higher arousal components. Interestingly, this observation could 
explain the equal prevalence of EDS in PD-wo and PD-OSAS, while the higher arousal index 
is most likely responsible for the significantly increased sleepiness in Co-OSAS compared to 
Co-wo. 
Interestingly, PD-OSAS patients with autonomic disturbances had significantly slower 
heart rates during most sleep stages as compared to PD-OSAS without autonomic 
disturbances. Since sympathetic cardiac denervation has been shown to be more frequent and 
more pronounced in PD patients with orthostatic hypotension [26], our finding suggests that 
OSAS in PD may lead to changes of time-domain HRV variables – i.e. decrease of mean R-R 
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interval – if there is little or no ANS dysfunction. However, since the presence of autonomic 
disturbances in our patients was detected only by history and clinical examination, this 
finding has to be replicated in a study, which includes cardiovascular reflex testing.  
The clinical implications and the prognostic significance of our observations are not 
clear at this moment. It is tempting to speculate that the autonomic deficiency might protect 
PD patients with OSAS to some degree from the typical cardiovascular consequences. In this 
line, Cochen De Cock et al. did not find an association between OSAS and cardiovascular 
events in PD patients [27]. In addition, a case-control study of 178 untreated PD patients 
showed a lower prevalence of vascular risk factors such as diabetes, hypertension, and blood 
lipid levels than matched non-PD patients [28]. 
Limitations of this study are its retrospective design and the fact that most PD patients 
were under dopaminergic treatment at the time of the HRV analysis. Levodopa has been 
reported to alter cardiovascular reflexes. Thus, we cannot exclude that dopaminergic drugs 
have influenced the autonomic function in our PD patients. On the other hand, Goldstein et al. 
found that cardiac sympathetic denervation was not related to levodopa treatment [29]. 
Likewise, other groups also failed to show any correlation between daily levodopa dose and 
HRV parameters [30].  
In conclusion, our results suggest that the overall pathophysiological profile of OSAS 
in PD differs from that typically observed in OSAS patients without underlying 
neurodegenerative disorder. Since the ANS is cardinally involved in mediating the various 
consequences of OSAS – ranging from immediate effects on cortical arousal reaction to long-
term cardiovascular morbidity – the specific disease-modifying impact of ANS dysfunction in 
PD patients with OSAS warrants further investigation. 
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Table 1 Demographic data, clinical characteristics and polysomnographic findings of 
control subjects (n = 62) and PD patients (n = 62) 
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Table 2 Comparison of OSAS severity between control subjects and PD patients. 
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Table 3 Dopaminergic treatment at the moment of polysomnography is similar 
between PD patients with and without OSAS 
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Table 4 Spearman correlation coefficients (rho) between HRV variables and various 
polysomnographic findings in 62 PD patients and 62 control subjects.  
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Figure 1 Comparison of HRV variables between control subjects with and without 
OSAS and PD patients with and without OSAS. 
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Figure 2 While in control subjects the apnea-hypoponea index (AHI) strongly 
correlated with the arousal index, this association was lacking in PD patients. 
Similarly, significant correlations between arousal index and LF/HF ratios in 
NREM1 and NREM2 sleep were found in control subjects but not in PD 
patients.  
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Figure 3 PD-OSAS with autonomic disturbances (AD) (n = 15) had a significantly 
higher mean R-R interval in wake (p = 0.02), NREM1 (p = 0.007), NREM2 
(p = 0.03) and REM sleep (p = 0.01) compared to PD-OSAS without clinical 
signs of AD (n = 12). Conversely, the mean R-R interval did not differ 
between PD-wo with and without AD. 
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Abstract 
Background: Obstructive sleep apnea syndrome (OSAS) is associated with repeated apnea-
induced sympathetic surges leading to specific alterations of the power spectrum of heart rate 
variability (HRV). Sympathetic dysfunction evolves early in idiopathic Parkinson’s disease 
(PD), but the consequences on cardiac autonomic response to OSAS have not been studied so 
far in PD patients. 
Methods: Sixty-two patients with PD (35 without OSAS (PD-wo), 27 with OSAS (PD-
OSAS)) and 62 age-matched control subjects (25 without OSAS (Co-wo), 37 with OSAS 
(Co-OSAS)) were included. HRV variables – including mean R-R interval, standard deviation 
of all normal-to-normal R-R intervals (SDNN), both low frequency (LF) and high frequency 
(HF) power bands, and the LF/HF ratio – were computed automatically from full-night 
polysomnography and calculated separately for each sleep stage. 
Results: HRV variables were similar in PD-wo and PD-OSAS. In contrast, Co-OSAS showed 
significantly higher LF power in NREM1 and NREM2 sleep and higher LF/HF ratio in 
NREM1, NREM2 and slow wave sleep than Co-wo. Similarly, correlations between HRV 
variables and parameters of OSAS severity were found only in controls but not in PD patients. 
Conclusion: Our results suggest that the sympathetic response to OSAS is blunted in PD, 
giving further clinical evidence of the sympathetic denervation commonly observed in this 
neurodegenerative disorder. 
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Introduction 
Increased vascular morbidity in patients with obstructive sleep apnea syndrome 
(OSAS) is believed to be caused by abnormal autonomic cardiovascular regulation [1]. In this 
line, obstructive sleep-related apnea events are characterized by progressive bradycardia 
during respiratory effort and abrupt tachycardia after reopening of the airways, which leads to 
cyclical variations of heart rate [2]. Studies using spectral analysis of heart rate variability 
(HRV) have shown that OSAS is accompanied by an increase of low frequency power bands, 
which is believed to reflect sympathetic activity [3]. Likewise, both increased sympathetic 
nerve activity and high levels of circulating norepinephrine during wakefulness have been 
observed in patients with OSAS [4-6]. During sleep, obstructive apneas are accompanied by 
transient vasoconstriction in the limbs, again suggesting apnea-induced sympathetic activation 
[7]. Finally, there is evidence that alteration of HRV and overactivity of the sympathetic 
nervous system is reversible during treatment with continuous positive airway pressure [6, 8]. 
The effects of OSAS on cardiac autonomic function may be altered in patients with 
neurological conditions affecting the autonomic nervous system (ANS). Earlier studies in 
patients with familial dysautonomia or pure autonomic failure reported that even severe 
apneas were not associated with the usual cardiac response, suggesting a decoupling of the 
heart rate from the respiratory cycle in neurodegenerative disease [9, 10].  
In idiopathic Parkinson’s disease (PD), there is growing evidence for sympathetic 
denervation of the heart. Neuroimaging studies using different sympathiconeural imaging 
agents demonstrated reduced sympathetic innervation of the heart in patients with PD [11, 
12]. Considering the important pathophysiological involvement of the ANS in OSAS and its 
primary impairment in PD, it is surprising that the cardiac autonomic response to OSAS has 
not yet been studied in PD patients. Therefore, the primary goal of this study was to test the 
hypothesis whether the normal sympathetic response to OSAS is blunted in PD. In addition, 
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we aimed at identifying possible consequences of this sympathetic denervation in PD patients 
with OSAS. 
 
Methods  
This retrospective study was conducted at the Department of Neurology of the 
University Hospital of Zurich, Switzerland.  
 Subjects. We analyzed the data of 115 consecutive patients with idiopathic Parkinson’s 
disease (PD). All patients were examined in our Movement Disorders outpatient clinic and in 
our sleep laboratory between January 2005 and June 2010. Fifty-three PD patients were 
diagnosed with OSAS (PD-OSAS), and 59 had no clinical or polysomnographic signs of 
OSAS (PD-wo). Three PD patients with apneas of mainly central origin were excluded. 
As control groups, we included 80 consecutive patients, who have been diagnosed 
with OSAS (Co-OSAS), and 53 subjects without OSAS (Co-wo), i.e. without 
polysomnographic abnormalities. We excluded subjects with cardiovascular disease, cardiac 
arrhythmia, concomitant diabetes, neurological disorders, additional sleep-wake disorders 
such as narcolepsy, restless legs syndrome (RLS), periodic limb movements during sleep 
(PLMS), rapid eye movement (REM) sleep behavior disorder (RBD), and intake of 
betablockers. 
PD patients were older than control subjects (PD-wo: 65 ± 10 years, PD-OSAS: 66 ± 8 
years; Co-wo: 46 ± 15 years, Co-OSAS: 51 ±13 years). Since age is known to have a major 
impact on cardiac autonomic function, we aimed for a better matching of age and selected the 
62 youngest PD patients and the 62 oldest control subjects for this study. We therefore 
included 35 PD-wo (mean age: 58 ± 6 years), 27 PD-OSAS (59 ± 6 years), 25 Co-wo (57 ± 12 
years), and 37 Co-OSAS (59 ± 8 years). 
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Clinical assessments. The diagnosis of Parkinson’s disease was made according to 
international diagnostic criteria [13]. Motor symptoms and disease severity were assessed 
according to the motor subset of the Unified Parkinson’s Disease Rating Scale (UPDRS III) in 
off condition and by the Hoehn & Yahr staging, respectively. Excessive daytime sleepiness 
(EDS) was diagnosed if the score of the Epworth sleepiness scale was ≥ 10.  
Polysomnography. All subjects underwent one full-night polysomnography 
(Somnologica software). The recordings were performed from 11.00 PM until 7.00 AM using a 
16-channel recording system (Embla A10, Embla, Broomfield, CO). Polysomnography 
included electroencephalographic recording (C3-A2, O2-A1), electro-oculography, chin and 
bilateral anterior tibialis muscles electromyography, oro-nasal thermistor, nasal flow pressure 
sensor and measurement of thoracic and abdominal movements (impedance). Oxygen 
saturation (SaO2) was continuously determined with a finger oximeter. Scoring of sleep stages 
and respiratory events was performed visually using standardized criteria [14, 15]. Apnea was 
defined by a cessation of oro-nasal airflow longer than 10 seconds, and hypopnea by a 
reduction of oro-nasal airflow by at least 50% lasting more than 10 seconds and accompanied 
by an arousal or SaO2 reduction of ≥ 3%. The apnea-hypopnea index (AHI) was calculated by 
the mean number of apneas and hypopneas per hour. Furthermore, mean SaO2, time with 
SaO2 below 90% (SaO2 < 90%), and oxygen desaturation-index (ODI) were calculated. OSAS 
was diagnosed in the presence of AHI ≥ 5/h with predominantly obstructive apneic events.  
Heart rate variability analysis. Polysomnography included a two-channel 
electrocardiogram (ECG) which allowed subsequent analysis of heart rate variability (HRV) 
by means of a specific HRV-module of the Somnologica software. Heart rate is expressed as 
average R-R interval in milliseconds, i.e. the mean interval between successive normal QRS 
complexes. HRV gives information about how the heart rate varies in time. All R-R intervals 
were processed; artifacts were identified and removed by a specific detection algorithm. 
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Polysomnographic recordings were divided into continuous 5-minute segments. The most 
prevailing sleep stage was allocated to every 5-minute segment allowing estimation of mean 
values per sleep. Calculation of HRV variables in relation to sleep stages is necessary because 
there is considerable variability of HRV variables between different sleep stages, as shown in 
healthy subjects [16].  
For each 5-minute segment, both time-domain and frequency-domain HRV parameters 
were computed. The time-domain HRV variables are calculated based on different aspects of 
the beat-to-beat intervals [16]. For the purpose of this study, the time-domain pattern was 
estimated by assessing the mean R-R intervals and the standard deviation of normal R-R 
intervals (SDNN) for each consecutive 5-minute segment. The frequency-domain HRV 
variables give general information on the power distribution across frequencies. They were 
obtained by a Fast Fourier spectral analysis of the R-R sequence. The power was calculated 
for low frequency (LF, 0.04 – 0.15 Hz) and high frequency bands (HF, 0.15 – 0.40). In 
addition, LF/HF ratio was calculated. Extensive literature exists on the physiological and 
clinical interpretation of the different power bands [17]. Briefly, the HF power is considered 
to reflect the parasympathetic (vagal) modulation of the heart rate, whereas the LF power 
reflects both sympathetic and parasympathetic activity [17]. The LF/HF ratio is believed to be 
a measure of the sympatho-vagal balance; higher values for this ratio may therefore imply 
either an increase in sympathetic dominance or a shift towards decreased vagal tone, or both. 
Data analysis and statistics. Statistical analyses were performed using SPSS (version 
19.0). Group data are described by means and standard deviations (SD). For univariate 
analysis we used Student’s t and Mann–Whitney U tests for numerical scale variables and χ2-
test for nominal scale variables. Testing of differences in HRV variables and demographic 
data between multiple groups was performed by the Kruskal-Wallis H test. We used 
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Spearman rho coefficient for correlation analysis between polysomnographic findings and 
HRV variables. Significance was accepted at p < 0.05. 
 
Results 
Demographic, clinical and polysomnographic data of the 62 control subjects and the 
62 PD patients are given in Table 1. The four groups did not differ in age and sex distribution. 
Group comparisons did not reveal any differences in the quantitative distribution of sleep 
stages. In control subjects but not in PD patients, the group with OSAS had higher arousal 
indices (20.3 ± 20.1 vs. 10.6 ± 7, p = 0.01). The prevalence of EDS was significantly higher in 
Co-OSAS compared to Co-wo (p = 0.04) and PD-OSAS (p = 0.04), while there were no 
differences in EDS between PD-OSAS and PD-wo. OSAS severity was similar between PD-
OSAS and Co-OSAS for most parameters, but oxygen desaturation was milder in PD-OSAS 
(Table 2).  
In terms of PD symptoms, PD-wo and PD-OSAS had similar prevalences of 
dyskinesia (36% vs. 33%, p = 0.54), wearing-off (33% vs. 30%, p = 0.51), hallucinations 
(17% vs. 29%, p = 0.28), RBD (62% vs. 71%, p = 0.32), insomnia (56% vs. 52%, p = 0.48) 
and autonomic disturbances (58% vs. 59%, p = 0.59). Furthermore, PD-wo and PD-OSAS did 
not differ in disease duration, disease severity and dopaminergic treatment (Table 1 and 3).   
Heart rate variability measures: comparison between Co-wo and PD-wo. In all 
behavioral stages, the mean R-R interval was lower (faster heart rate) in Co-wo than in PD-
wo (wake: 869 ± 115ms vs. 964 ± 182ms, p = 0.02; NREM1: 927 ± 136ms vs. 1033 ± 201ms, 
p = 0.02; NREM2: 938 ± 141ms vs. 1035 ± 198ms, p = 0.03; SWS: 909 ± 141ms vs. 1036 ± 
210ms, p = 0.009; REM: 919 ± 123ms vs. 1011 ± 189ms, p = 0.03). On the other hand, 
SDNN and the frequency-domain indices LF, HF and the LF/HF ratio were similar in Co-wo 
and PD-wo (Figure 1).  
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Heart rate variability measures: comparison between Co-wo and Co-OSAS. In control 
subjects, the presence of OSAS was associated with a significant increase in the LF 
component in both NREM1 and NREM2 sleep and an increase in the LF/HF ratio in NREM1, 
NREM2 and slow wave sleep (Figure 1). Values for mean R-R and SDNN did not differ 
between the two groups. 
Heart rate variability measures: comparison between Co-OSAS and PD-OSAS. The 
mean R-R interval and SDNN were similar between Co-OSAS and PD-OSAS. In Co-OSAS, 
however, the LF component was higher during wakefulness (p = 0.04), NREM1 (p = 0.02) 
and REM sleep (p = 0.02) and the LF/HF ratio was higher during NREM1 (p = 0.04) and 
REM sleep (p = 0.008) (Figure 1). 
Heart rate variability measures: comparison between PD-wo and PD-OSAS. The two 
PD groups did not differ in any of the HRV measures (Figure 1). 
Correlates of HRV parameters. In control subjects, AHI significantly correlated with 
LF and LF/HF ratio in both NREM1 and NREM2 sleep, and AHI was inversely correlated 
with HF during wakefulness and NREM1 sleep (Table 4). Similar correlations were revealed 
for ODI. In PD patients, on the other hand, AHI and ODI did not correlate with any of the 
HRV variables.  
Correlates of cortical arousal reaction. In control subjects – but not in PD patients – 
significant correlations were found between arousal index and HRV measures (Table 4). In 
addition, while control subjects showed a highly significant correlation between AHI and 
arousal index (rho = 0.6, p < 0.001), this relationship was not found in PD patients (rho = 
0.06, p = 0.64) (figure 2).         
Influence of autonomic disturbances in PD-OSAS. PD-OSAS patients with a history or 
clinical signs of autonomic disturbances (AD) (56%) – including obstipation (n = 9), urinary 
incontinence (n = 4), erectile dysfunction (n = 8), orthostatic dysregulation (n = 3) and 
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sweating disturbances (n = 4) – had significantly lower heart rates in wakefulness, NREM1, 
NREM2 and REM sleep compared to PD-OSAS without AD (44%) (Figure 3).  
 
Discussion 
The main finding of our study is the lack of difference in HRV variables between PD 
patients with and without OSAS. In control subjects, on the other hand, the presence of OSAS 
was associated with a significant increase in the low frequency power spectrum during 
NREM1 and NREM2 sleep and of the LF/HF ratio during NREM1, NREM2 and slow wave 
sleep. In other words, PD patients lack the normal sympathetic response to OSAS, thus 
supporting our initial hypothesis. In the same line and again in contrast to controls, parameters 
of OSAS severity such as AHI, ODI and SaO2 < 90%  did not correlate with any HRV 
parameters in PD patients. Further novel findings of this study comprise the reduced cortical 
arousal frequency of PD-OSAS compared to Co-OSAS, and the effect of autonomic 
disturbances on heart rate in PD-OSAS. 
The increase of LF power and LF/HF ratio’s in the control group with OSAS indicates 
enhanced sympathetic drive induced by the repeated apneic events, which is in line with 
previous studies [1]. To our best knowledge, however, cardiac autonomic response to OSAS 
has not been assessed yet in PD. Several mechanisms may contribute to the observed impaired 
cardiac autonomic response to OSAS in PD. First, it is conceivable that the blunted effect of 
OSAS on cardiac autonomic function reflects the loss of cardiac sympathetic noradrenergic 
innervation in PD. Evidence of cardiac sympathetic denervation comes mainly from 
neuroimaging studies, demonstrating decreased myocardial radioactivity after injection of 
sympathiconeural imaging agents in a majority of PD patients. Using 
123
I-
metaiodobenzylguinidine scanning, cardiac sympathetic denervation was found in early stages 
of PD, and even in the absence of clinical signs of autonomic failure [18]. In accordance with 
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these findings, a postmortem pathology study found a marked loss of tyrosine hydroxylase 
immunoreactivity, a marker for sympathetic nerves, in epicardial nerves or myocardial tissue 
[12].  
Second, autonomic dysfunction in PD is not limited to the heart. According to the 
study of Braak et al., the neurodegenerative process in many PD patients begins in the 
medulla oblongata and progresses in an ascending way to involve, already at early stages, 
various nuclei of the brainstem and also the hypothalamus and other parts of the basal ganglia 
[19]. The dorsal nucleus of the vagus and the locus coeruleus (LC) are among the first 
structures to be affected by the disease process. While the former gives rise to 
parasympathetic vagal neurons, the latter represents the principal source of brain 
norepinephrine. Besides of its major role in mediating arousal and shifts of behavior, the LC 
is also believed to be implicated in the central regulation of cardiovascular function [20]. It is 
therefore conceivable that destruction of pathways of the central autonomic nervous system 
involved in the regulation of cardiovascular function may additionally contribute to the 
neurocardiological abnormalities in PD patients with OSAS.  
Third, differences in OSAS characteristics between PD patients and control subjects 
should be taken into consideration. Although our two groups with OSAS did not differ in 
AHI, ODI, mean apnea duration and mean SaO2, the PD patients with OSAS maintained a 
more favorable respiratory profile, as reflected by less pronounced minimal SaO2 and fewer 
time spent with SaO2 < 90%.  
An unexpected observation of the present study was the lack of correlation between 
AHI and arousal index in PD patients – in controls this relationship was highly significant. 
Several reasons may explain this decrease of arousability in PD. First, sympathetic activation, 
as measured by heart rate spectral analysis, has been reported to precede visually detected 
cortical arousals [21]. Thus, an intact sympathetic nervous system may play a relevant role in 
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conveying the end-apnea effort to a cortical arousal reaction. Second, Onodera et al. studied 
ventilatory response to hypoxia and perception of dyspnoea in 25 PD patients and found a 
subnormal hypoxic response accompanied by an impaired perception of dyspnea [22]. Third, 
multiple components of the central arousal system are known to be damaged in PD, including 
the noradrenergic LC, the serotonergic dorsal raphe, the cholinergic pedunculopontine 
nucleus, the hypothalamic hypocretin system and the cholinergic neurons in the basal 
forebrain [23]. Intriguingly, the assumption of a decreased arousability seems to be 
inconsistent with the fact that OSAS severity tended to be milder in PD patients, because one 
would expect more severe apneas under this condition. On the other hand, however, even in 
healthy subjects about 30% of apneas and hypopneas are not accompanied by cortical arousals 
[24]. Furthermore, factors such as deeper sleep stage or higher sleep pressure are known to 
increase the cortical arousal threshold to respiratory events [25]. In other words, cortical 
arousal must not be regarded as a necessary prerequisite for apnea termination, but rather as a 
cortical consequence, which depends on the intensity of the inspiratory effort and on the 
integrity of several components of the central arousal system. Presumably, mechanoreceptor 
feedback from the respiratory muscles to the medullary respiration center can bring apneas to 
an end without activation of higher arousal components. Interestingly, this observation could 
explain the equal prevalence of EDS in PD-wo and PD-OSAS, while the higher arousal index 
is most likely responsible for the significantly increased sleepiness in Co-OSAS compared to 
Co-wo. 
Interestingly, PD-OSAS patients with autonomic disturbances had significantly slower 
heart rates during most sleep stages as compared to PD-OSAS without autonomic 
disturbances. Since sympathetic cardiac denervation has been shown to be more frequent and 
more pronounced in PD patients with orthostatic hypotension [26], our finding suggests that 
OSAS in PD may lead to changes of time-domain HRV variables – i.e. decrease of mean R-R 
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interval – if there is little or no ANS dysfunction. However, since the presence of autonomic 
disturbances in our patients was detected only by history and clinical examination, this 
finding has to be replicated in a study, which includes cardiovascular reflex testing.  
The clinical implications and the prognostic significance of our observations are not 
clear at this moment. It is tempting to speculate that the autonomic deficiency might protect 
PD patients with OSAS to some degree from the typical cardiovascular consequences. In this 
line, Cochen De Cock et al. did not find an association between OSAS and cardiovascular 
events in PD patients [27]. In addition, a case-control study of 178 untreated PD patients 
showed a lower prevalence of vascular risk factors such as diabetes, hypertension, and blood 
lipid levels than matched non-PD patients [28]. 
Limitations of this study are its retrospective design and the fact that most PD patients 
were under dopaminergic treatment at the time of the HRV analysis. Levodopa has been 
reported to alter cardiovascular reflexes. Thus, we cannot exclude that dopaminergic drugs 
have influenced the autonomic function in our PD patients. On the other hand, Goldstein et al. 
found that cardiac sympathetic denervation was not related to levodopa treatment [29]. 
Likewise, other groups also failed to show any correlation between daily levodopa dose and 
HRV parameters [30].  
In conclusion, our results suggest that the overall pathophysiological profile of OSAS 
in PD differs from that typically observed in OSAS patients without underlying 
neurodegenerative disorder. Since the ANS is cardinally involved in mediating the various 
consequences of OSAS – ranging from immediate effects on cortical arousal reaction to long-
term cardiovascular morbidity – the specific disease-modifying impact of ANS dysfunction in 
PD patients with OSAS warrants further investigation. 
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Table 1 Demographic data, clinical characteristics and polysomnographic findings of 
control subjects (n = 62) and PD patients (n = 62) 
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Table 2 Comparison of OSAS severity between control subjects and PD patients. 
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Table 3 Dopaminergic treatment at the moment of polysomnography is similar 
between PD patients with and without OSAS 
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Table 4 Spearman correlation coefficients (rho) between HRV variables and various 
polysomnographic findings in 62 PD patients and 62 control subjects.  
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Figure 1 Comparison of HRV variables between control subjects with and without 
OSAS and PD patients with and without OSAS. 
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Figure 2 While in control subjects the apnea-hypoponea index (AHI) strongly 
correlated with the arousal index, this association was lacking in PD patients. 
Similarly, significant correlations between arousal index and LF/HF ratios in 
NREM1 and NREM2 sleep were found in control subjects but not in PD 
patients.  
         
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
22 
Figure 3 PD-OSAS with autonomic disturbances (AD) (n = 15) had a significantly 
higher mean R-R interval in wake (p = 0.02), NREM1 (p = 0.007), NREM2 
(p = 0.03) and REM sleep (p = 0.01) compared to PD-OSAS without clinical 
signs of AD (n = 12). Conversely, the mean R-R interval did not differ 
between PD-wo with and without AD. 
 
 
 
 
 
  
1 
Table 1  
 
 
    Co-wo  Co-OSAS  p   PD-wo PD-OSAS   p 
n    25 (40%) 37 (60%)     35 (56%) 27 (44%) 
 
Demographic data: 
Male, n    16 (64%) 27 (73%)  NS   19 (54%) 20 (67%)  NS 
Age, y    57 ± 12  59 ± 8   NS   58 ± 6  59 ± 6   NS 
 
Clinical characteristics: 
BMI, kg/m
2
   26.2 ± 5.3 28.7 ± 4.7  NS   22.6 ± 3.1 28.0 ± 4.9           <0.001  
ESS    8.0 ± 4.5 11.2 ± 5.6  0.01   8.3 ± 4.3 9.7 ± 4.7  NS 
EDS (ESS ≥ 10), n  10 (40%) 24 (67%)  0.04   13 (39%) 11 (41%)  NS 
Disease duration, y          7.2 ± 4.4 8.1 ± 6.9  NS 
UPDRS III           22.8 ± 10.9 26.4 ± 13.9  NS 
Hoehn & Yahr           2.3 ± 0.8 2.5 ± 0.8  NS  
 
Polysomnographic findings: 
Total sleep time, min  359 ± 64 357 ± 65  NS   330 ± 81 340 ± 67  NS 
Sleep latency to NREM2 23.2 ± 16.1 31.8 ± 32.7  NS   26.8 ± 38.1 22.5 ± 17.2  NS 
Arousal index, /h  10.5 ± 7.0 20.3 ± 20.1            0.009
a 
  8.0 ± 4.6 10.6 ± 9.4  NS 
Sleep efficiency, %  81.4 ± 11.8 81.6 ± 12.0  NS   76.7 ± 15.3 78.5 ± 12.7  NS 
Sleep stage transitions, /h 17.7 ± 5.8 21.1 ± 7.3  0.047   19.0 ± 5.9 23.0 ± 21.9  NS 
PLMS, /h   0.9 ± 2.3 6.7 ± 9.9  0.001   5.5 ± 10.6 17.6 ± 35.9  NS 
Wake, %   18.9 ± 11.5 17.8 ± 11.9  NS
   
22.6 ± 15.2 21.4 ± 12.5  NS 
NREM1, %   12.3 ± 5.7 15.8 ± 13.3  NS
   
12.4 ± 5.4 11.9 ± 8.0  NS 
NREM2, %   40.0 ± 9.2 37.1 ± 11.5  NS   37.8 ± 11.2 40.3 ± 10.6  NS  
SWS, %   13.5 ± 7.9 16.5 ± 8.5  NS   14.0 ± 9.4 10.7 ± 6.9  NS 
REM, %   15.4 ± 6.9 12.3 ± 5.3  NS   13.3 ± 6.0 15.7 ± 8.6  NS 
 
 
a
 Mann-Whitney U test  
NS: not significant   BMI: Body Mass Index   ESS:  Epworth Sleepiness Scale   EDS: Excessive daytime sleepiness   UPDRS III: Unified Parkinson’s Disease 
Rating Scale (Part III=motor score)   NREM sleep: Non-Rapid-Eye Movements   SWS: Slow wave sleep   AHI: Apnea-Hypopnea-Index 
Table(s)
  
1 
Table 4 
 
   Arousal index AHI       mean SaO2 SaO2<90% ODI  
        
                             CS PD CS PD CS PD CS PD CS PD 
 
Wake:  
Mean R-R interval -0.21  0.16 -0.04 -0.03  0.29* -0.03 -0.21  0.02 -0.07     -0.05 
LF    0.06  0.19  0.09 -0.02  0.19 -0.09 -0.08  0.07  0.07     -0.07 
HF   -0.33**  0.16 -0.27* -0.07  0.23  0.12 -0.24 -0.02 -0.26*   -0.09 
LF/HF ratio   0.25* -0.03  0.23  0.08 -0.09 -0.18  0.12  0.04  0.23 0.03 
 
NREM1 sleep: 
Mean R-R interval -0.19  0.11 -0.06 -0.06  0.38**  0.06 -0.30* -0.04 -0.08     -0.09 
LF     0.23  0.22  0.29*  0.07  0.12 -0.03 -0.09 -0.003  0.23     -0.04 
HF   -0.25*  0.18 -0.30* -0.11  0.25*  0.20 -0.22 -0.06 -0.26*   -0.09 
LF/HF ratio   0.36**  0.03  0.46*** 0.12 -0.13 -0.24  0.15  0.04  0.38** 0.05 
 
NREM2 sleep: 
Mean R-R interval -0.17  0.13  0.01  0.001  0.34** -0.01 -0.25  0.01  0.01     -0.04 
LF     0.16  0.05  0.28*  0.07  0.16 -0.19 -0.07  0.09  0.23     -0.03 
HF   -0.23  0.14 -0.23  0.05  0.27*  0.12 -0.25* -0.003 -0.19     -0.04 
LF/HF ratio   0.28* -0.15  0.39** -0.02 -0.14 -0.29*  0.19  0.003  0.33** -0.07 
 
Slow wave sleep: 
Mean R-R interval -0.05  0.15  0.15 -0.03  0.27* -0.01 -0.16 -0.007  0.14     -0.08 
LF   -0.09  0.02  0.14  0.15   0.26* -0.22 -0.22  0.15  0.11 0.01 
HF   -0.20  0.21 -0.12  0.18  0.31*  0.11 -0.19 -0.06 -0.07      0.01 
LF/HF ratio   0.10 -0.20  0.24 -0.04 -0.11 -0.30*  0.05  0.12  0.20     -0.04 
 
REM sleep: 
Mean R-R interval -0.13  0.08  0.04  0.003  0.29* -0.09 -0.18  0.05  0.03     -0.01 
LF    -0.14  0.02 -0.01 -0.09  0.32* -0.04 -0.28* -0.003 -0.06     -0.14 
HF    -0.10  0.21 -0.04  0.16  0.10  0.07 -0.03  0.08  0.004    0.12 
LF/HF ratio   0.02 -0.21  0.02 -0.25  0.20 -0.21 -0.19 -0.05 -0.04    -0.24 
 
*  p < 0.05     ** p < 0.01     *** p < 0.001 
 
 
 
AHI: Apnea-Hypopnea Index     CS: control subjects     HF: high frequency power     LF: low 
frequency power     LF/HF ratio: ratio between low frequency and high frequency power     NREM 
sleep: Non Rapid Eye Movement Sleep     ODI: Oxygen Desaturation Index     PD: Parkinson’s 
Disease     REM: Rapid Eye Movement     SaO2: blood oxygen saturation     SaO2<90%: blood 
oxygen saturation below 90%      
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Co-wo: control subjects without OSAS       Co-OSAS: control subjects with OSAS       PD-wo: PD patients 
without OSAS       PD-OSAS: PD patients with OSAS       LF: low frequency power       HF: high frequency 
power       LF/HF: ratio between low frequency and high frequency power 
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